Insights On Downstream Manufacturing

  1. Characterization Of Antibody‑Drug Conjugates Using 2D-LC And Native MS 6/18/2026

    Accurate DAR measurement is critical for ADC performance, yet traditional methods can compromise integrity. See how an MS workflow combining HIC, heart-cutting, and SEC enables more reliability.

  2. Analysis Of Free Drug Content In Antibody-Drug Conjugate 6/18/2026

    Free drug content can compromise ADC safety and performance if not carefully measured. A multidimensional LC/Q-TOF workflow pairs SEC and reversed-phase separation to enable sensitive detection.

  3. Creative Chromatography Solutions For Complex Small Molecules 6/18/2026

    Chromatographic modeling enables smarter purification. Discover how digital tools, fraction mapping, and expert execution can improve yield for the most challenging small-molecule separations.

  4. Where Speed Meets Complexity In Bioprocess Development 6/18/2026

    Bioprocessing faces mounting pressure to compress timelines, especially for mAbs, while complex modalities like bispecifics and gene therapies introduce technical challenges. Process intensification, scale-up translation, and comparability risks remain critical hurdles.

  5. Considerations For Scaling Downstream Viral Vector Manufacturing 6/12/2026

    In this segment from the Bioprocess Online Live event, "Downstream Decisions To Maximize Viral Vector Yields And Reduce COGs," panelists Hung Trinh, Ph.D., and Nathalie Clément, Ph.D., advise our audience on when to think about scaling a process and discuss which unit operations are most difficult to scale.

  6. Quantifying Viral Vector Yield Losses Downstream 6/12/2026

    In this segment from the Bioprocess Online Live event, "Downstream Decisions To Maximize Viral Vector Yields And Reduce COGs," panelists Hung Trinh, Ph.D., CEO at Vertex Biopharm Consulting, and Nathalie Clément, Ph.D., senior VP of vector development at Siren Biotechnology, contextualize the kind of losses seen in downstream viral vector purification, which can sometimes be as high as 80%.

  7. Finding Balance Between Viral Vector Purity And Quantity 6/12/2026

    In this segment from the Bioprocess Online Live event, "Downstream Decisions To Maximize Viral Vector Yields And Reduce COGs," panelists Hung Trinh, Ph.D., and Nathalie Clément, Ph.D., discuss the tradeoff between yield recovery and product quality. They agree that a focus on product purity is a necessity, but this purity comes at the cost of reduced yields downstream.

  8. Using Residual DNA Quantification Data To De-Risk mAb Development 6/11/2026

    Residual DNA quantitation offers more than impurity measurement. When used across process steps, it helps compare purification performance, identify risks early, and ensure assays remain reliable.

  9. SPTFF High Concentration mAb Formulation Case Study 6/10/2026

    Learn how single-pass tangential flow approaches improve efficiency, scalability, and product quality while addressing key development and processing challenges.

  10. Every Milliliter Matters: Maximizing Yield In Fill-Finish 6/4/2026

    A technical overview of minimizing product loss in aseptic fill‑finish processes, highlighting key loss points and practical strategies to improve yield, efficiency, and manufacturing consistency.